lansoprazole has been researched along with famotidine in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (34.29) | 18.2507 |
| 2000's | 30 (42.86) | 29.6817 |
| 2010's | 14 (20.00) | 24.3611 |
| 2020's | 2 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ogawa, N | 1 |
| Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA | 1 |
| Inatomi, N; Nagaya, H; Satoh, H | 1 |
| Inatomi, N; Nagaya, H; Satoh, H; Shino, A; Takami, K | 1 |
| Fukuda, M; Higashi, T; Imaizumi, T; Kawano, S; Miura, N; Miyajima, K; Mukuda, T; Noguchi, M; Tatsumi, T; Tsuji, S | 1 |
| Ashida, K; Katsu, K; Miyoshi, H; Sakaguchi, M; Umegaki, E | 1 |
| Motoo, Y; Okai, T; Sawabu, N; Songür, Y; Watanabe, H | 1 |
| Fukuchi, S; Hashimoto, M; Hoshihara, Y; Iguchi, D; Kimura, T; Sugawara, K; Takemoto, T; Tanaka, T; Yamamoto, T | 2 |
| Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y | 1 |
| Hoshino, E; Miki, K; Umeda, N | 1 |
| Asaka, M; Hokari, K; Takeda, H | 1 |
| Chijiiwa, Y; Maruoka, A; Nawata, H; Tanaka, M | 1 |
| Agostini, H; Lemaire, M; Poynard, T | 1 |
| Inada, I; Satoh, H | 1 |
| Asano, S; Inatomi, N; Murakami, I; Nagaya, H; Satoh, H; Yukishige, K | 1 |
| Asano, S; Inada, I; Inatomi, N; Murakami, I; Satoh, H | 1 |
| Berstad, A; Hatlebakk, JG | 1 |
| Hibi, T; Ishii, H; Iwai, N; Miyayama, A; Mori, M; Oonuki, M; Suzuki, H; Suzuki, M; Tsunematsu, N | 1 |
| Haga, Y; Nakamura, Y; Nakatsura, T; Ogawa, M; Sameshima, H; Shibata, Y; Tanimura, M | 1 |
| Kanayama, S | 1 |
| Saika, M; Senba, E; Ueyama, T | 1 |
| Itoh, M; Joh, T; Kurokawa, T; Sasakii, M; Seno, K; Tsuchida, K; Yokoyama, Y | 1 |
| Dave, B; Rubin, W | 1 |
| Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S | 1 |
| Fujita, N; Kassai, K; Kondo, M; Naito, Y; Tanaka, Y; Yoshida, N; Yoshikawa, T | 1 |
| Endo, M; Sugihara, K | 1 |
| Miehsler, W; Oberhuber, T; Püspök, A; Vogelsang, H | 1 |
| Furuta, T; Hanai, H; Ishizaki, T; Kajimura, M; Ohashi, K; Shirai, N; Xiao, F | 1 |
| Matsuoka, T; Miyazawa, K; Mizokami, Y; Nakamura, H; Narushima, K; Otsubo, T; Shiraishi, T | 1 |
| Shcherbynina, MB | 1 |
| Fukao, K; Homma, M; Itagaki, F; Kohda, Y; Yuzawa, K | 1 |
| Adachi, K; Fujishiro, H; Kinoshita, Y; Komazawa, Y; Mihara, T | 1 |
| Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T | 1 |
| Scarpignato, C | 1 |
| Futagami, S; Hiratsuka, T; Kusunoki, M; Miyake, K; Nakajima, A; Nishigaki, H; Sakamoto, C; Shinji, Y; Suzuki, K; Tatsuguchi, A; Tsukui, T; Ueki, N; Wada, K; Yoshino, S | 1 |
| Furuta, T; Hishida, A; Kajimura, M; Nakamura, A; Okudaira, K; Shirai, N; Sugimoto, M | 1 |
| Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T | 1 |
| Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y | 1 |
| Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M | 1 |
| Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G | 1 |
| Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Furukubo, T; Hirata, S; Izumi, S; Kadowaki, D; Matsunaga, C; Satoh, M; Uchida, T; Yamakawa, T | 1 |
| Iida, T; Mine, S; Okada, Y; Tabata, T; Tanaka, Y | 1 |
| Cadirci, E; Dengiz, GO; Halici, Z; Odabasoglu, F; Suleyman, H | 1 |
| Kobayashi, M; Kouzu, T; Odaka, T; Seza, A; Suzuki, T; Yamaguchi, T; Yokosuka, O | 1 |
| Aoyama, T; Ishihara, Y; Kawamura, I; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Ojio, S; Okubo, M; Takasugi, N; Takemura, G; Tanaka, S; Ushikoshi, H; Yamaki, T; Yasuda, S | 1 |
| Bidwell, KL; Brackbill, ML; Brophy, DF; Brophy, GM | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Shirai, N; Sugimoto, M; Sugimura, H; Tanaka, T; Uotani, T; Yamade, M | 1 |
| Antonioli, L; Awwad, O; Basolo, F; Blandizzi, C; Colucci, R; Fornai, M; Fulceri, F; Natale, G; Tuccori, M; Ugolini, C | 1 |
| Kato, M; Nema, H | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M | 1 |
| Miura, M; Niioka, T; Sawada, K; Takahashi, N | 1 |
| Kadota, J; Murakami, K; Tamura, A | 1 |
| Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS | 1 |
| Alhassanin, SA; El-Berri, EI; El-Haggar, SM; Hegazy, SK | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
9 review(s) available for lansoprazole and famotidine
| Article | Year |
|---|---|
Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine; Time Factors; Wound Healing | 1995 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidone; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Metoclopramide; Nizatidine; Omeprazole; Pantoprazole; Piperidines; Proton Pump Inhibitors; Ranitidine; Sucralfate; Sulfoxides | 1996 |
[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1999 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Markov Chains; Meta-Analysis as Topic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic | 2004 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Quality of Life | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic | 2005 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; Female; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Ranitidine; Skin Tests | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
25 trial(s) available for lansoprazole and famotidine
| Article | Year |
|---|---|
[Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Famotidine; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Stomach Ulcer | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence | 1992 |
Gastric ulcer healing and basic fibroblast growth factor: effects of lansoprazole and famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Female; Fibroblast Growth Factor 2; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach; Stomach Ulcer | 1995 |
Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Depression, Chemical; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Comparison of lansoprazole and famotidine for gastric ulcer by endoscopic ultrasonography: a preliminary trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Famotidine; Female; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer; Ultrasonography | 1995 |
Effects of lansoprazole on mucosal regeneration in patients with gastric ulcers: evaluation using an electronic endoscope with a magnifying function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastric Mucosa; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regeneration; Stomach Ulcer | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulcer Agents; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors | 1995 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies; Endoscopy, Digestive System; Esophagitis, Peptic; Famotidine; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Retrospective Studies | 1995 |
The therapeutic effect of proton pump inhibitors on Helicobacter pylori-positive gastric ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Multivariate Analysis; Nizatidine; Omeprazole; Patient Dropouts; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer; Treatment Outcome | 1999 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Diseases, Functional; Diarrhea; Eating; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Ranitidine | 1999 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonography; Enzyme Inhibitors; Esophagitis, Peptic; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Mucous Membrane; Muscle, Smooth; Omeprazole; Proton Pump Inhibitors | 2000 |
[Long-term maintenance treatment of reflux esophagitis resistant to H2-RA with PPI (lansoprazole)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Drug Resistance; Enzyme Inhibitors; Esophagitis, Peptic; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Long-Term Care; Omeprazole; Proton Pump Inhibitors | 2000 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Negative Reactions; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Piperidines; Predictive Value of Tests; Quinolones; Urea | 2003 |
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Treatment Outcome | 2005 |
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Famotidine; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; Drug Tolerance; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Middle Aged; Omeprazole; Pain Measurement; Prospective Studies; Proton Pump Inhibitors | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibitors; Esophagitis, Peptic; Famotidine; Female; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quality of Life; Recurrence; Treatment Outcome | 2005 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Middle Aged; Proton Pump Inhibitors; Proton Pumps; Treatment Failure | 2006 |
Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Laser-Doppler Flowmetry; Male; Middle Aged; Mucous Membrane; Proton Pump Inhibitors; Regional Blood Flow; Surveys and Questionnaires; Ultrasonography | 2008 |
Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Critical Illness; Famotidine; Female; Gastric Acidity Determination; Gastric Juice; Gastrointestinal Hemorrhage; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lansoprazole; Male; Middle Aged; Neurosurgical Procedures; Prospective Studies; Racial Groups; Suspensions; Young Adult | 2010 |
Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Famotidine; Female; Gastric Acidity Determination; Gastric Mucosa; Genotype; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Male; Proton Pump Inhibitors; Severity of Illness Index; Stomach Ulcer; Young Adult | 2011 |
Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Endoscopy; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Wound Healing | 2010 |
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Gastroscopy; Humans; Lansoprazole; Male; Mucous Membrane; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2012 |
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antagonists; Humans; Incidence; Lansoprazole; Male; Middle Aged; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Recurrence; Secondary Prevention; Stomach Ulcer | 2020 |
Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cyclophosphamide; Doxorubicin; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Proton Pump Inhibitors; Rituximab; Transforming Growth Factor beta; Treatment Outcome; Vincristine | 2021 |
36 other study(ies) available for lansoprazole and famotidine
| Article | Year |
|---|---|
Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bethanechol Compounds; Dogs; Famotidine; Female; Gastric Acid; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Pentagastrin; Peptones; Pylorus; Rats; Rats, Inbred Strains | 1991 |
Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Esophagitis, Peptic; Famotidine; Gastric Mucosa; Immersion; Lansoprazole; Omeprazole; Peptic Ulcer; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Psychological | 1991 |
Mucosal regeneration of gastric ulcer confirmed by electronic endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Electronics, Medical; Famotidine; Female; Gastric Mucosa; Gastroscopy; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Regeneration; Stomach Ulcer | 1995 |
Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Famotidine; Gastric Acid; Gastric Acidity Determination; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Monitoring, Physiologic; Omeprazole | 1995 |
Endoscopic ultrasonographic evaluation of gastric ulcer healing on treatment with proton pump inhibitors versus H2-receptor antagonists.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Famotidine; Female; Gastroscopy; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Nizatidine; Omeprazole; Piperidines; Proton Pump Inhibitors; Stomach Ulcer; Ultrasonography, Interventional; Wound Healing | 1994 |
Capsaicin-sensitive sensory neurons are involved in bicarbonate secretion induced by lansoprazole, a proton pump inhibitor, in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Bicarbonates; Capsaicin; Duodenum; Famotidine; Histamine H2 Antagonists; Intestinal Mucosa; Lansoprazole; Male; Neurons, Afferent; Omeprazole; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley; Stimulation, Chemical; Vasoactive Intestinal Peptide | 1996 |
[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Famotidine; Gastric Mucosa; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Indomethacin; Lansoprazole; Male; Omeprazole; Ranitidine; Rats; Rats, Sprague-Dawley | 1996 |
[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Animals; Anti-Ulcer Agents; Famotidine; Gastric Acid; Gastric Mucosa; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Ranitidine; Rats; Rats, Sprague-Dawley; Stress, Physiological | 1996 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-8; Lansoprazole; Male; Middle Aged; Neutrophils; Omeprazole; Peroxidase; Proton Pump Inhibitors; Stomach Ulcer | 1997 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Stomach Neoplasms; Time Factors | 1998 |
Prostacyclin analog prevents stress-induced expression of immediate early genes and gastric mucosal lesions in the rat stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Epoprostenol; Famotidine; Gastric Mucosa; Genes, Immediate-Early; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar; Regional Blood Flow; Stress, Physiological | 1999 |
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Cell Culture Techniques; Endothelium; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Neutrophils; Omeprazole; Proton Pump Inhibitors; Ranitidine; Stomach Ulcer | 2000 |
Impact of different therapeutic regimens on the outcome of patients with Crohn's disease of the upper gastrointestinal tract.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Crohn Disease; Data Interpretation, Statistical; Disaccharides; Duodenal Diseases; Esophageal Diseases; Famotidine; Female; Humans; Lansoprazole; Male; Mannitol; Mesalamine; Middle Aged; Omeprazole; Permeability; Proton Pumps; Retrospective Studies; Stomach Diseases; Treatment Outcome | 2001 |
Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Circadian Rhythm; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Heterozygote; Homozygote; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors | 2002 |
[Treatment of NSAIDs induced ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Famotidine; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Misoprostol; Omeprazole; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2002 |
[Effect of various antisecretory drugs on morphological changes in rat gastric mucosa in experimental stomach ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Epithelium; Famotidine; Gastric Mucosa; Lansoprazole; Male; Microcirculation; Octreotide; Omeprazole; Rats; Rats, Wistar; Stomach Ulcer; Treatment Outcome | 2002 |
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Interactions; Famotidine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Calcium Carbonate; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Phosphorus; Proton Pump Inhibitors; Renal Dialysis | 2007 |
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Animals; Anti-Ulcer Agents; Antioxidants; Catalase; Cyclopropanes; Dose-Response Relationship, Drug; Famotidine; Gastrointestinal Agents; Glutathione Reductase; Glutathione Transferase; Histamine H2 Antagonists; Indomethacin; Intubation, Gastrointestinal; Lansoprazole; Male; Molecular Structure; Peroxidase; Quinolines; Ranitidine; Rats; Rats, Sprague-Dawley; Stomach; Stomach Ulcer; Sulfides; Superoxide Dismutase | 2007 |
Four-day continuous gastric pH monitoring following anti-acid secretory drug administration: cross-over test to assess the early effects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Famotidine; Gastric Acid; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Proton Pump Inhibitors; Time Factors | 2008 |
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Angina Pectoris; Coronary Angiography; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Stroke Volume; Ventricular Function, Left | 2008 |
Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Esomeprazole; Famotidine; Gastric Acid; Gastric Mucosa; Histamine H2 Antagonists; Immunohistochemistry; Indomethacin; Ki-67 Antigen; Lansoprazole; Male; Malondialdehyde; Proliferating Cell Nuclear Antigen; Proton Pump Inhibitors; Rats; Rats, Wistar; Stomach Ulcer; Time Factors; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nizatidine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2012 |
Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Cohort Studies; Cross-Sectional Studies; Drug Administration Schedule; Endoscopy; Famotidine; Female; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Prevalence; Steroids | 2013 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |